Skip to main content

12-09-2019 | Multiple sclerosis | Video

ECTRIMS 2019: Prolonged exposure to disease-modifying therapies reduces the risk for disability progression in RRMS

Giuseppe Lucisano reports real-world data showing protection against disability progression in patients with relapsing-remitting multiple sclerosis over more than 10 years of follow-up (3:19).

Funding for independent interviews at ECTRIMS 2019 was provided by F.Hoffmann-La Roche Ltd, Basel, Switzerland.

The Big Multiple Sclerosis Data Network project was supported by Biogen International (Zug, Switzerland).